Last reviewed · How we verify
NCT03973307
UroX Biomarker Bladder Cancer Study
trial testing UroX bladder cancer biomarker test in Bladder Cancer in 100 participants. Status unknown.
1 July 2020
Quick facts
| Lead sponsor | East and North Hertfordshire NHS Trust |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 21 January 2019 |
| Primary completion | 1 July 2020 |
| Estimated completion | 1 July 2025 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- UroX bladder cancer biomarker test
Conditions studied
- Bladder Cancer — all drugs for Bladder Cancer →
Sponsor
East and North Hertfordshire NHS Trust
Who can join
18 and older, any sex, with Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective observational study looking at urine samples from participants under referral for a standard of care investigative cystoscopy and biopsy. The study aims to test if the UroX™ biomarker (a measurable indicator of a biological condition) can be detected in urine samples from participants who may later test positive following a biopsy for bladder cancer. The study aims to assess the value of the biomarker as a screening tool for bladder cancer. Patients with and those without bladder cancer are required for the study.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Urine-Based Approaches for Screening, Diagnosis, and Surveillance of Urothelial Carcinoma.
Bilim V, Hoshi S. · · 2026 · PMID 41893002 · DOI 10.3390/jpm16030135
Verify or expand the search:
- PubMed search for NCT03973307
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bladder Cancer
Currently open trials in the same condition.
- NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
- NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
- NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting
Other East and North Hertfordshire NHS Trust trials
Trials by the same sponsor.
- NCT07069998 — AI-guided AF Treatment · NA · not yet recruiting
- NCT06915909 — Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial · NA · not yet recruiting
- NCT06863090 — In Vivo Dosimetry for Brachytherapy Study · recruiting
- NCT06623123 — Oto Smartphone App in Treating Tinnitus Amongst Adult Patients Compared with Standard Talking Therapies · Phase 3 · recruiting
- NCT06400927 — Safety of AI-Powered Virtual Assistant in Outpatient Management of Heart Failure · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03973307 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by East and North Hertfordshire NHS Trust
- Last refreshed: 4 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03973307.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing